Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis [3]

Indian Journal of Dermatology, Venereology and Leprology

Volumn 73, Issue 1, 2007, Pages 53-54

  Sharma, V K ^a   Prasad, H R Y ^a   Sethuraman, G ^a   Khaitan, B K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; STIBOGLUCONATE SODIUM;

ADULT; ARTHRALGIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; LETTER; LEUKOPENIA; MALE; MYALGIA; PATIENT COMPLIANCE; SIDE EFFECT; SKIN LEISHMANIASIS; THROMBOPHLEBITIS; TREATMENT DURATION;

EID: 33847388363     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.30657     Document Type: Letter

References (4)

1. Control of leishmaniases. Report of a WHO expert committee. World Health Organ Tech Rep Ser 1990;793:1-158.
2. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: Report from the center of Indian epidemic. Clin Infect Dis 2000;31:1104-7.
3. Ramesh V. Treatment of post-kala-azar dermal leishmaniasis. Int J Dermatol 1994;33:153-6.
4. Ramesh V, Mukherjee A. Post kala-azar dermal leishmaniasis. Int J Dermatol 1995;34:85-91.